Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;16(4):36-47.
doi: 10.1080/15265161.2016.1145282.

An Ethical Exploration of Barriers to Research on Controlled Drugs

Michael H Andreae  1 , Evelyn Rhodes  2 , Tyler Bourgoise  2 , George M Carter  3 , Robert S White  4 , Debbie Indyk  2 , Henry Sacks  2 , Rosamond Rhodes  2
Affiliations

An Ethical Exploration of Barriers to Research on Controlled Drugs

Michael H Andreae et al. Am J Bioeth. 2016.

Abstract

We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of legal consequences, stigma associated with abuse and populations using illicit drugs, and lack of funding may, however, limit research on their considerable therapeutic potential. We review the surprisingly sparse literature and address the particular ethical concerns pertinent to research with illicit and addictive substances, such as undue inducement, informed consent, therapeutic misconception, and risk to participants, researchers, and institutions. We consider the perspectives of key research stakeholders and explore whether they may be infected with bias. We conclude by proposing an empirical research agenda to provide an evidentiary basis for ethical reasoning.

Keywords: biomedical research; confidentiality and privacy; human subjects research; informed consent; institutional review board; research ethics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Catch 22 Cartoon
See this image and copyright information in PMC

Comment in

References

    1. Publications.parliament.uk [January 22 2015];'House Of Commons - Science And Technology - Written Evidence'. 2015 http://www.publications.parliament.uk/pa/cm200506/cm.
    1. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy A randomized placebo-controlled trial. Neurology. 2007;68(7):515–-521. - PubMed
    1. Abrams DI. Medical marijuana: tribulations and trials. J Psychoactive Drugs. 1998;30(2):163–-169. - PubMed
    1. Aggarwal Sunil K., Carter Gregory T., Sullivan Mark D., ZumBrunnen Craig, Morrill Richard, Mayer Jonathan D. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153–-168. - PubMed
    1. Alexander Michelle. The new Jim Crow: Mass incarceration in the age of colorblindness. The New Press; 2012.

Publication types